Loading...
•
Sep 30, 2022
Amedisys Q3 2022 Earnings Report
Reported financial results for Q3 2022 and updated 2022 guidance.
Key Takeaways
Amedisys reported a net service revenue increase of $4.5 million to $558.0 million compared to $553.5 million in 2021. Net income attributable to Amedisys, Inc. was $25.6 million compared to $45.0 million in 2021, with adjusted diluted earnings per share of $1.15 compared to $1.53 in 2021.
Signed an innovative case rate arrangement with CVS/Aetna.
Signed a comprehensive care at home partnership with The University of Arkansas for Medical Science.
Enhancing benefit packages in 2023 and working on flexible scheduling to increase clinical capacity.
Focusing on centralization and automation to remove the administrative load for caregivers and care center leadership.
Forward Guidance
Amedisys updated its 2022 guidance, anticipating adjusted net service revenue in the range of $2.224 billion to $2.230 billion, adjusted EBITDA in the range of $253 million to $258 million, and adjusted diluted earnings per share in the range of $4.82 to $4.93 based on an estimated 32.7 million shares outstanding.
Positive Outlook
- Adjusted net service revenue is anticipated to be in the range of $2.224 billion to $2.230 billion.
- Adjusted EBITDA is anticipated to be in the range of $253 million to $258 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $4.82 to $4.93.
- Guidance is based on the current operating environment.
- The company is working on flexible scheduling and focusing on centralization and automation.
Challenges Ahead
- COVID-19 continues to evolve in its disruptions to the healthcare systems and the economy.
- Any future regulations or government interventions could impact the ability to achieve this guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...